JP2013518124A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518124A5 JP2013518124A5 JP2012551302A JP2012551302A JP2013518124A5 JP 2013518124 A5 JP2013518124 A5 JP 2013518124A5 JP 2012551302 A JP2012551302 A JP 2012551302A JP 2012551302 A JP2012551302 A JP 2012551302A JP 2013518124 A5 JP2013518124 A5 JP 2013518124A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament according
- administered
- medicament
- day
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 21
- 210000002381 Plasma Anatomy 0.000 claims 3
- 108010050904 Interferons Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 238000009835 boiling Methods 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000035533 AUC Effects 0.000 claims 1
- 230000035783 C(max) Effects 0.000 claims 1
- 102100008763 IFNA2 Human genes 0.000 claims 1
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 1
- 210000004185 Liver Anatomy 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 229960000329 Ribavirin Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 230000036231 pharmacokinetics Effects 0.000 claims 1
Claims (21)
- HCVに感染した患者を処置するためにVX−222と同時にまたは連続的に共投与するための、VX−950を含む医薬。
- VX−222の薬物動態を改善するための、請求項1に記載の医薬。
- 患者の血漿、血液または肝臓におけるVX−222への暴露が改善される、請求項2に記載の医薬。
- 患者の血漿中、VX−222への暴露が、VX−950を投与しないときのVX−222への血漿暴露と比較して2−6倍増大する、請求項2または3に記載の医薬。
- 共投与したVX−222のC(trough)レベル、C (max) 値またはAUC値の少なくとも一つが増大する、請求項2−4のいずれか1項に記載の医薬。
- VX−222が、各投与にて20mgないし2,000mg投与される、請求項1−5のいずれか1項に記載の医薬。
- VX−222が、各投与にて400mg投与される、請求項6に記載の医薬。
- VX−222が1日2回投与される、請求項7に記載の医薬。
- VX−950が、750mgを1日3回投与される、請求項1−8のいずれか一項に記載の医薬。
- VX−950が、各投与にて1,125mg投与される、請求項1−8のいずれか一項に記載の医薬。
- HCVに感染した患者の処置においてVX−222およびVX−950を同時にまたは連続的に投与するための医薬であって、ここで、VX−222は、各投与にて20mgないし400mg投与され、VX−950は、各投与にて100mgないし1500mg投与される、医薬。
- VX−950が、750mgを1日3回投与される、請求項11に記載の医薬。
- VX−950が、1125mgを1日2回投与される、請求項11に記載の医薬。
- VX−222が、各投与にて400mg投与される、請求項11−13のいずれか一項に記載の医薬。
- VX−222が1日2回投与される、請求項11−14のいずれか一項に記載の医薬。
- VX−950およびVX−222以外の1種以上のさらなるHCV薬と組み合わせて使用する、請求項1−15のいずれか一項に記載の医薬。
- さらなるHCV薬がインターフェロンである、請求項16に記載の医薬。
- インターフェロンが、ペグ化インターフェロン α−2aまたはペグ化インターフェロン α−2bである、請求項17に記載の医薬。
- リバビリンと組み合わせて使用する、請求項1−18のいずれか一項に記載の医薬。
- 8週ないし24週間の期間に、VX−950およびVX−222を共投与する、請求項1−19のいずれか一項に記載の医薬。
- VX−950およびVX−222を、12週間共投与する、請求項20に記載の医薬。
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29964310P | 2010-01-29 | 2010-01-29 | |
US61/299,643 | 2010-01-29 | ||
US30850610P | 2010-02-26 | 2010-02-26 | |
US61/308,506 | 2010-02-26 | ||
US30911710P | 2010-03-01 | 2010-03-01 | |
US61/309,117 | 2010-03-01 | ||
US32439510P | 2010-04-15 | 2010-04-15 | |
US61/324,395 | 2010-04-15 | ||
PCT/US2011/022854 WO2011094489A1 (en) | 2010-01-29 | 2011-01-28 | Therapies for treating hepatitis c virus infection |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013518124A JP2013518124A (ja) | 2013-05-20 |
JP2013518124A5 true JP2013518124A5 (ja) | 2014-03-20 |
Family
ID=43901208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012551302A Pending JP2013518124A (ja) | 2010-01-29 | 2011-01-28 | C型肝炎ウイルス感染の処置のための治療法 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20130034522A1 (ja) |
EP (1) | EP2528605A1 (ja) |
JP (1) | JP2013518124A (ja) |
KR (1) | KR20120139699A (ja) |
CN (1) | CN102844030A (ja) |
AU (1) | AU2011210795A1 (ja) |
CA (1) | CA2788348A1 (ja) |
IL (1) | IL220937A0 (ja) |
MX (1) | MX2012008652A (ja) |
RU (1) | RU2012136824A (ja) |
SG (1) | SG182589A1 (ja) |
TW (1) | TW201130502A (ja) |
WO (1) | WO2011094489A1 (ja) |
ZA (1) | ZA201205547B (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
JP2013531011A (ja) * | 2010-06-28 | 2013-08-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス感染の処置または予防のための化合物および方法 |
WO2012040127A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
UY34402A (es) | 2011-10-21 | 2013-05-31 | Abbvie Inc | Métodos para el tratamiento de hcv |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
CN104023726A (zh) * | 2011-10-21 | 2014-09-03 | 艾伯维公司 | 用于治疗hcv的一种或多种daa的联合治疗(例如,与abt-072或abt-333) |
CA2860234A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
WO2013142159A1 (en) * | 2012-03-21 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
NZ631601A (en) | 2012-03-21 | 2016-06-24 | Alios Biopharma Inc | Solid forms of a thiophosphoramidate nucleotide prodrug |
NZ630805A (en) | 2012-03-22 | 2016-01-29 | Alios Biopharma Inc | Pharmaceutical combinations comprising a thionucleotide analog |
US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1302468T3 (da) | 1992-12-29 | 2009-03-02 | Abbott Lab | Fremgangsmåder og mellemprodukter til fremstilling af forbindelser, der inhiberer retroviral protease |
IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
EP0902782A1 (en) | 1996-04-23 | 1999-03-24 | Vertex Pharmaceuticals Incorporated | Urea derivatives as inhibitors of impdh enzyme |
DK0966465T3 (da) | 1997-03-14 | 2003-10-20 | Vertex Pharma | Inhibitorer af IMPDH-enzymer |
US20040058982A1 (en) | 1999-02-17 | 2004-03-25 | Bioavailability System, Llc | Pharmaceutical compositions |
CN1196687C (zh) | 1999-03-19 | 2005-04-13 | 沃泰克斯药物股份有限公司 | Impdh酶抑制剂 |
EP1299527A2 (en) | 2000-06-28 | 2003-04-09 | National Research Council Of Canada | Helicobacter dd-heptosyltransferase |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
EP1539188B1 (en) | 2001-01-22 | 2015-01-07 | Merck Sharp & Dohme Corp. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
KR100900304B1 (ko) | 2001-06-11 | 2009-06-02 | 바이로켐 파마 인코포레이티드 | 플라비 바이러스 감염용 항바이러스제로서의 티오펜 유도체 |
CA2369711A1 (en) | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
CA2369970A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
US6642204B2 (en) | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
US7091184B2 (en) | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
IL166640A0 (en) | 2002-08-01 | 2006-01-15 | Pharmasset Ltd | Compounds with the bicyclo Ä4.2.1Ü nonane system for the treatment of flaviviridae infections |
CA2413705A1 (en) | 2002-12-06 | 2004-06-06 | Raul Altman | Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions |
US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7098231B2 (en) | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
WO2004073599A2 (en) | 2003-02-18 | 2004-09-02 | Pfizer Inc. | Inhibitors of hepatitis c virus, compositions and treatments using the same |
ATE486889T1 (de) | 2003-03-05 | 2010-11-15 | Boehringer Ingelheim Int | Peptidanaloga mit inhibitorischer wirkung auf hepatitis c |
JP4550824B2 (ja) | 2003-03-05 | 2010-09-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎抑制化合物 |
KR101115294B1 (ko) | 2003-05-21 | 2012-04-12 | 베링거 인겔하임 인터내셔날 게엠베하 | C형 간염 억제제 화합물 |
WO2005018330A1 (en) | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Dosing regimen for flaviviridae therapy |
CA2538843A1 (en) | 2003-09-12 | 2005-03-24 | Vertex Pharmaceuticals Incorporated | Animal model for protease activity and liver damage |
US6933760B2 (en) | 2003-09-19 | 2005-08-23 | Intel Corporation | Reference voltage generator for hysteresis circuit |
EA200600498A1 (ru) | 2003-09-22 | 2006-10-27 | Бёрингер Ингельхайм Интернациональ Гмбх | Макроциклические пептиды, проявляющие противовирусную активность в отношении вируса гепатита с |
US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
ES2358333T3 (es) | 2004-01-21 | 2011-05-09 | Boehringer Ingelheim International Gmbh | Péptidos macrocíclicos con acción contra el virus de la hepatitis c. |
US20050187192A1 (en) | 2004-02-20 | 2005-08-25 | Kucera Pharmaceutical Company | Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses |
EP2626354A1 (en) | 2004-02-20 | 2013-08-14 | Boehringer Ingelheim International GmbH | Viral polymerase inhibitors |
US20050288333A1 (en) | 2004-06-08 | 2005-12-29 | Kem William R | Controlling angiogenesis with anabaseine analogs |
TWI437990B (zh) | 2004-10-29 | 2014-05-21 | Vertex Pharma | Vx-950之醫藥用途 |
EP1991229A2 (en) | 2006-02-27 | 2008-11-19 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
CA2646229A1 (en) | 2006-03-16 | 2007-09-27 | Vertex Pharmaceuticals Incorporated | Deuterated hepatitis c protease inhibitors |
EP2001498A4 (en) | 2006-03-20 | 2013-01-23 | Vertex Pharma | PHARMACEUTICAL COMPOSITIONS |
GEP20125378B (en) | 2006-03-20 | 2012-01-10 | Vertex Pharma | Pharmaceutical compositions |
JP5290186B2 (ja) * | 2006-11-15 | 2013-09-18 | ヴァイロケム ファーマ インコーポレイテッド | フラビウイルス感染症の治療または予防用のチオフェン類似体 |
MX2009006806A (es) | 2006-12-22 | 2009-08-27 | Vertex Pharma | Secado por rocio fluidizado. |
AP2009004960A0 (en) | 2007-02-27 | 2009-08-31 | Vertex Pharma | Co-crystals and pharmaceutical compositions comprising the same |
CA2688554A1 (en) | 2007-05-21 | 2008-11-27 | Vertex Pharmaceuticals Incorporated | Dose forms comprising vx-950 and their dosage regimen |
EP2170888B1 (en) * | 2007-06-29 | 2015-04-22 | Gilead Sciences, Inc. | Purine derivatives and their use as modulators of toll-like receptor 7 |
US8536187B2 (en) * | 2008-07-03 | 2013-09-17 | Gilead Sciences, Inc. | 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections |
-
2011
- 2011-01-28 TW TW100103512A patent/TW201130502A/zh unknown
- 2011-01-28 CA CA2788348A patent/CA2788348A1/en not_active Abandoned
- 2011-01-28 AU AU2011210795A patent/AU2011210795A1/en not_active Abandoned
- 2011-01-28 MX MX2012008652A patent/MX2012008652A/es active IP Right Grant
- 2011-01-28 JP JP2012551302A patent/JP2013518124A/ja active Pending
- 2011-01-28 EP EP11703776A patent/EP2528605A1/en not_active Withdrawn
- 2011-01-28 SG SG2012053120A patent/SG182589A1/en unknown
- 2011-01-28 KR KR1020127021714A patent/KR20120139699A/ko not_active Application Discontinuation
- 2011-01-28 CN CN2011800168308A patent/CN102844030A/zh active Pending
- 2011-01-28 WO PCT/US2011/022854 patent/WO2011094489A1/en active Application Filing
- 2011-01-28 RU RU2012136824/15A patent/RU2012136824A/ru not_active Application Discontinuation
-
2012
- 2012-07-12 IL IL220937A patent/IL220937A0/en unknown
- 2012-07-23 ZA ZA2012/05547A patent/ZA201205547B/en unknown
- 2012-07-27 US US13/559,995 patent/US20130034522A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013518124A5 (ja) | ||
Flamm et al. | Ledipasvir/Sofosbuvir with Ribavirin for the Treatment of HCV in Patients with Decompensated Cirrhosis: Preliminary Results of a Prospective, Multicenter Study: 239 | |
JP2014530874A5 (ja) | ||
JP2012517478A5 (ja) | ||
RU2012136824A (ru) | Способы лечения вирусной инфекции гепатита с | |
JP2014515373A5 (ja) | ||
JP2015505565A5 (ja) | ||
JP2019517542A5 (ja) | ||
JP2012515184A5 (ja) | ||
JP2013155188A5 (ja) | ||
RU2012148710A (ru) | Органическое соединение для применения при лечении рака печени | |
JP2017506624A5 (ja) | ||
JP2015524444A5 (ja) | ||
JP2018513188A5 (ja) | ||
AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
JP2015515985A5 (ja) | ||
JP2008517991A5 (ja) | ||
JP2013541583A5 (ja) | ||
JP2015517523A5 (ja) | ||
JP2016505050A5 (ja) | ||
JP2020503269A5 (ja) | ||
JP2017514911A5 (ja) | ||
NZ588655A (en) | Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin | |
JP2011500589A5 (ja) | ||
JP2017061488A5 (ja) |